Nanjing Leads Biolabs Co., Ltd.
Nanjing Leads Biolabs is a Hong Kong-listed (HKEX: 9887) antibody developer. Its lead candidate opamtistomig (LBL-024) is under priority BLA review in China, and the company has begun dosing lupus patients in a Phase 1 study of LBL-047.
| Headquarters | Nanjing, China |
|---|---|
| Listing | HKEX:09887 |
| Lead asset / stage | opamtistomig (LBL-024) BLA under priority review — China |
| Latest event | Leads Biolabs dosed the first SLE patient in Part B of its Phase 1 LBL-047 trial. |